ICU Medical, Inc. — Q2 2020 Form 10-Q
Reporting period: Three and six months ended June 30, 2020. All financial figures below are in millions of U.S. dollars, except per-share data. ICU Medical develops, manufactures and sells infusion therapy, IV solutions and critical-care products globally.
Key financial results
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | $303.4 | $312.3 | $632.0 | $643.2 |
| Gross profit | $106.3 | $103.9 | $227.7 | $239.2 |
| Gross margin | 35.0% | 33.3% | 36.0% | 37.2% |
| Operating income | $19.6 | $26.3 | $45.6 | $56.6 |
| Net income | $18.9 | $22.8 | $35.7 | $53.8 |
| Diluted EPS | $0.88 | $1.06 | $1.66 | $2.50 |
| Operating cash flow | — | $68.7 | $2.3 |
- Revenue mix: Q2 Infusion Systems revenue grew to $91.1 million from $81.3 million, while Infusion Consumables declined to $111.0 million from $117.7 million and IV Solutions declined to $89.2 million from $102.6 million. Critical Care increased to $12.1 million from $10.7 million.
- Liquidity and debt: Cash and cash equivalents were $446.1 million; short-term investments were $14.6 million, for total cash and investments of $460.7 million, versus $292.6 million at year-end 2019. The company had drawn $150.0 million under its revolving credit facility, with no remaining availability. The facility matures in November 2022. ICU Medical reported compliance with its financial covenants at quarter-end.
- Balance sheet: Total assets were $1.86 billion and stockholders’ equity was $1.41 billion at June 30, 2020. Current liabilities included $150.0 million of short-term debt.
Changes versus the prior comparable period
- Q2 revenue fell 2.9% year over year; first-half revenue fell 1.7%. The Q2 gross margin improved, primarily because the prior-year period included one-time IV Solutions charges. First-half gross margin declined, mainly due to lower IV Solutions manufacturing volumes and unfavorable mix.
- Q2 and first-half net income declined. Comparability is affected by unusual items: 2020 included a $2.7 million expense from an increase in the Pursuit earn-out fair value, while 2019 included gains of $39.5 million in Q2 and $47.2 million in the first half from remeasurement of the HIS earn-out. Restructuring, strategic transaction and integration costs were also lower: $6.5 million in Q2 2020 versus $37.0 million in Q2 2019.
- First-half operating cash flow increased to $68.7 million from $2.3 million. Changes in working capital still used $38.7 million in cash in 2020; operating cash flow in 2019 was substantially affected by working-capital movements and the earn-out remeasurement.
- Other expense was $3.4 million for the first half of 2020, primarily reflecting $4.7 million of foreign-exchange losses, compared with $4.7 million of other income in the prior-year period.
Outlook, commentary and risks
- COVID-19: First-quarter customer stocking increased demand, particularly for IV Solutions and Infusion Systems. In Q2, demand for dedicated infusion sets and other disposable products weakened, while pump demand increased and partly offset the declines. Management said the duration and financial impact of the pandemic could not yet be reasonably estimated.
- Risks identified include production or supply-chain interruptions, changing hospital demand and customer credit, possible future demand declines after pandemic-related stocking, restricted hospital access delaying product implementations, higher operating costs, foreign-exchange volatility and delayed cost-saving initiatives.
- Capital spending: Management estimated 2020 capital expenditures of approximately $85 million to $90 million, with spending planned for manufacturing capacity, customer-placed infusion devices and IT. Actual spending may differ materially.
- Management stated existing cash and expected operating cash generation should fund operations for the next 12 months, while noting that a more severe or prolonged downturn could require alternative financing. The $150 million revolver borrowing was drawn as a precaution amid pandemic-related uncertainty and carries variable interest-rate exposure.
- Contingencies: Pfizer disputes ICU Medical’s determination that no payment is due under the HIS earn-out; unresolved issues may go to binding arbitration, expected to conclude in the second half of 2020. The Pursuit acquisition earn-out liability was $20.0 million at June 30, 2020, with potential additional consideration capped at $50.0 million. A saline antitrust case naming ICU Medical was dismissed with prejudice in April 2020; plaintiffs did not appeal.
- Remaining performance obligations included $10.7 million of equipment and software implementation revenue, substantially expected within three to six months, subject to COVID-19-related implementation restrictions. Management provided no broad revenue or earnings guidance in the supplied filing text.
Important facts for investors to verify
- Whether pandemic-related demand shifts in disposable products and infusion pumps persist, and whether customer stocking leads to weaker subsequent orders.
- Progress on hospital implementations and recognition of the $10.7 million of related remaining performance obligations.
- Outcome and timing of the Pfizer HIS earn-out dispute, and assumptions underlying the $20.0 million Pursuit earn-out valuation.
- Cash generation, planned capital expenditures, variable-rate interest costs and continued compliance with credit-facility covenants.
- Exposure to foreign-exchange movements, particularly given the first-half $4.7 million foreign-exchange loss and the company’s disclosed unhedged euro and Canadian-dollar positions.